Rapid Review: Sepsis

Richard H. Sinert, DO


April 08, 2022

The study found that UFH reduced the relative 28-day mortality rate by 16%, with no significant bleeding complications. Nearly all patients with sepsis experienced abnormalities in coagulation, ranging from minor changes to disseminated intravascular coagulation. Anticoagulants such as thrombomodulin and a tissue factor pathway inhibitor have been examined to ameliorate sepsis mortality and have proven ineffective thus far. However, in this study, researchers found that UFH plays more than a simple anticoagulant role and has numerous protective effects, such as enhancing endothelial barrier function and mediating nuclear factor kappa B activation.

Learn more about heparin.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.